NeOnc Technologies Holdings is trading 6.36% down at $3.24, despite positive Phase 2a NEO100 results released August 12, 2026.
- The study met its primary endpoint, with six-month progression-free survival of 48.9% versus a 20% benchmark and median overall survival of 26.09 months.
- August 13’s decline follows August 12’s 20.46% drop and August 11’s 24.29% gain, suggesting volatile post-catalyst trading.
- No reliable source explicitly attributes the decline to a specific company announcement; its exact cause remains unconfirmed.